MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.

MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib. Oncol Lett. 2018 Jan;15(1):963-971 Authors: Yu Q, Liu Y, Wen C, Zhao Y, Jin S, Hu Y, Wang F, Chen L, Zhang B, Wang W, Zhu Q, Guo R Abstract Dysregulation of microRNAs in various types of human cancer promote or suppress oncogenesis. MicroRNA (miR)-1 was previously revealed to function as a tumor suppressor in prostate cancer cells, and its expression was associated with reduced metastatic potential in lung cancer. The present study investigated the role of miR-1 and its association with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) in the pathophysiology of esophageal squamous cell carcinoma (ESCC), and analyzed the effects of miR-1 inhibitor or mimics on sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitors, the alterations of cell cycle distribution and apoptosis in ESCC cells. Compared with normal tissues, the level of miR-1 expression was significantly lower and PIK3CA expression was higher in ESCC tissues. The level of miR-1 expression was also inversely associated with the level of PIK3CA mRNA expression. Low miR-1 and high PIK3CA expression levels were strongly associated with lymph node metastasis, and the level of miR-1 expression was negatively associated with clinical Tumor-Node-Metastasis stage. Furthermore, exogenous expression of miR-1 inhibited growth, arrested cell cycle in...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

Conclusions: Sensitivity of thoracentesis for solid tumors varies significantly depending on the type of tumor and is lowest in those with sarcomas, head and neck malignancies, and renal cell cancers.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Substantial variation exists among US surgeons in how likely they are to omit axillary lymph node dissection in early breast cancer despite recommendations to do so under well-defined circumstances.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Primary pulmonary lymphoma is a relatively uncommon disease in both the thoracic and lymphoproliferative spectrum of cancers, accounting for only up to 1% of primary pulmonary malignancies and fewer than 1% of all lymphomas.1 Diagnosis requires pathologic confirmation of the lymphoproliferative disorder in the lungs, with no detectable extrathoracic manifestations of the disease for at least 3 months after the initial diagnosis to avoid accidental inclusion of lymphoma that has secondarily progressed to involve the lungs.
Source: Contemporary Diagnostic Radiology - Category: Radiology Tags: Article Source Type: research
Conclusions: The findings of the study convincingly suggest the presence of a stromal component in RB tumours. The interactions between stromal cells and tumour cells might be of profound importance in RB progression.Ocul Oncol Pathol
Source: Ocular Oncology and Pathology - Category: Opthalmology Source Type: research
We present the first case in the literature of a patient with recurrent vulvar cancer who was treated successfully with pembrolizumab. Caris next-generation testing revealed a PD-L1 and PD-1 mutation (PD-L1 positive, 2+, 100%). She attained a complete clinical remission after 2 cycles, and a CT scan after 6 cycles revealed a significant response by RECIST criteria. After completing 10 cycles, treatment was stopped due to complications of severe malnutrition related to narcotic abuse. A CT scan 10 weeks after the final treatment revealed no adenopathy. Pembrolizumab is a safe and effective chemotherapeutic agent to treat re...
Source: Gynecologic and Obstetric Investigation - Category: OBGYN Source Type: research
PROSTATE cancer symptoms include having a sudden urge to pass urine, and using the toilet more often than normal. But do you do this when you pee? Signs and treatment for prostate cancer revealed.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Publication date: 20 July 2015 Source:Clinica Chimica Acta, Volume 447 Author(s): Bin Wei , Chunmei Guo , Shuqing Liu , Ming-Zhong Sun Annexin A4 (Anxa4) is one of the Ca2+-regulated and phospholipid-binding annexin superfamily proteins. Anxa4 has a potential role in diagnosis, prognosis, and treatment of certain cancers. Studies indicate that Anxa4 up-regulation promotes the progression of tumor and chemoresistance of colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), endometrial carcinoma (EC), gastric cancer (GC), chemoresistant lung cancer (LC), malignant mesothelioma (MM), renal cell carcinoma (RCC)...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Abstract Annexin A4 (Anxa4) is one of the Ca(2+)-regulated and phospholipid-binding annexin superfamily proteins. Anxa4 has a potential role in diagnosis, prognosis and treatment of certain cancers. Studies indicate that Anxa4 up-regulation promotes the progression of tumor and chemo-resistance of colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), endometrial carcinoma (EC), gastric cancer (GC), chemo-resistant lung cancer (LC), malignant mesothelioma (MM), renal cell carcinoma (RCC), ovarian clear cell carcinoma (OCCC), cholangiocarcinoma, hepatocellular carcinoma (HCC), breast cancer (BC) and la...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
Conclusions The positive rate of s-NY-ESO-1-Abs was significantly higher in patients with esophageal cancer than in patients with the other types of cancers. On the basis of its high specificity and sensitivity, even in patients with stage I tumors, s-NY-ESO-1-Abs may be one of the first choices for esophageal cancer.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Lung Cancer | Prostate Cancer | Skin Cancer | Squamous Cell Carcinoma | Study